TY  -  
T1  - Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1 
SN  -  /  
UR  - http://hdl.handle.net/10138/334437 
T3  -  
A1  - Cervera-Carrascon, Victor; Quixabeira, Dafne C. A.; Santos, Joao M.; Havunen, Riikka; Milenova, Ioanna; Verhoeff, Jan; Heinio, Camilla; Zafar, Sadia; Garcia-Vallejo, Juan J.; van Beusechem, Victor W.; de Gruijl, Tanja D.; Kalervo, Aino; Sorsa, Suvi; Kanerva, Anna; Hemminki, Akseli 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and/or recruit different immune populations. T-cell enabling virotherapy could enhance the efficacy of immune checkpoint inhibitors, even in tumors resistant to these inhibitors. The T-cell potentiating virotherapy used here consisted of adenoviruses engineered t... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - cancer immunotherapy; oncolytic virus; adenovirus; checkpoint inhibitor resistance; tumor microenvironment; IMMUNE CHECKPOINT INHIBITORS; NECROSIS-FACTOR-ALPHA; T-CELL THERAPY; ACQUIRED-RESISTANCE; ONCOLYTIC VIRUSES; PD-1 BLOCKADE; COMBINATION; IMPROVES; LANDSCAPE; 3111 Biomedicine 
N1  -   
PP  -  
ER  -